• Mashup Score: 2

    EHA2022 Congress Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy led to improvement in overall survival for adults aged 18 to 75 with newly diagnosed FLT3-ITD–positive acute myeloid…

    Tweet Tweets with this article
    • RT @ASCOPost: Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy https://t.co/XIDqTAAUB9 #leusm #leukemia #…

    • Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy https://t.co/XIDqTAAUB9 #leusm #leukemia #hematology @DukeCancer #EHA22 #EHA2022

  • Mashup Score: 2

    In this video, Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses strategies to manage kidney disease in…

    Tweet Tweets with this article
    • Santosh Saraf (@UIHealth) shares some insights into the management of kidney disease in patients with sickle cell disease. Watch his interview here: 👉https://t.co/28JHZMxPtt👈 @EHA_Hematology #EHA2022 #HemOnc #RareDiseases #SickleCell #SCD